Mumbai: Piramal Critical Care, Inc. (PCC), an overseas subsidiary of Piramal Pharma Limited, has announced a collaboration with Blue-Zone Technologies Ltd. (Blue-Zone) to deploy full-lifecycle technology designed to capture, collect, and recycle waste anaesthetic gases.
By combining Blue-Zone’s innovative waste anaesthesia gas capture, collection, and processing technology with Piramal’s global manufacturing and marketing capabilities, the collaboration aims to support customers in minimizing the environmental impact of volatile anaesthetics.
The initiative is also expected to help ensure that these essential products remain the primary method of delivering general anaesthesia to patients worldwide.
Also Read: Biopharma SHAKTI Announced in Union Budget 2026-27 with ₹10,000 Crore Outlay
Pending regulatory approval in Europe for Blue-Zone’s Phoenix Deltasorb waste anaesthetic gas capture system, Blue-Zone will offer these systems to PCC’s customers across Europe, initially in France and Germany.
Blue-Zone will manage all activities related to supplying and deploying its systems within healthcare facilities.
PCC will process captured waste anaesthetic gas using Blue-Zone’s technology to produce Sevoflurane USP for human use in Canada.
Both organizations anticipate expanding the scope of waste anaesthetic gas capture, collection, recycling, and the marketing of Sevoflurane USP derived from recycled anaesthetic gas into additional geographies in the future.
Also Read: ProPharma Opens New Hyderabad Office to Accelerate Global Expansion
Piramal Critical Care Advances Sustainable Anaesthesia Solutions
Jeff Hampton, President and COO Piramal Critical Care, commented: “Piramal Critical Care is proud to partner with Blue-Zone on this innovative waste anaesthetic gas capture, collection, and recycling technology to help reduce waste and minimize environmental impact.
By introducing gas capture technology, hospitals can choose the inhaled anaesthetic that best meets clinical needs while also supporting more sustainable healthcare goals.
Inhaled anaesthetics are vitally important medicines that enable essential treatment for patients around the world. As a leading global manufacturer of general anaesthesia products, Piramal Pharma is committed to supporting clinicians, hospitals, and health systems with solutions that balance clinical performance and environmental responsibility.
Our focus is to ensure that patients continue to receive the critical care they need while advancing more sustainable approaches to anaesthesia.”
